Phase 1 N=8 Safety and Immunogenicity of Rotavirus Vaccine (RotaTeq(R)) in Infants With Short Bowel Syndrome
Short Bowel Syndrome
Primary: Safety and Tolerability of the Oral RotaTeq® Vaccine — 18; 3 Individual Adverse Events
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=1,715 Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
Meningitis · Meningococcal Meningitis · Meningococcal Infections
Primary: Percentage of Participants Achieving Vaccine Seroresponse Measured by Serum Bactericidal Assay Using Human Complement (hSBA) Against Meningococcal Serogroups A, C, Y…
Phase 2 N=14 Lonafarnib for Chronic Hepatitis D
Hepatitis D
Primary: Change in Quantitative Serum HDV RNA Levels After 28 Days of Lonafarnib Therapy. — -0.13; -0.73; -1.54 log(IU/ml) — p=0.03
Phase 3 N=570 Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)
Meningococcal Immunisation (Healthy Volunteers)
Primary: Percentage of Participants With Vaccine Seroresponse Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With MenACYW Conjugate Vaccine in Study MET59…
Phase 3 N=792 Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers
Dengue · Dengue Hemorrhagic Fever · Yellow Fever
Primary: Percentage of Flavi Virus (FV) Non-immune Participants With Seroconversion Against YF Antigen After Vaccination With Yellow Fever (YF) Vaccine (Stamaril®) Concomitantly…
Phase 4 N=23 Characterizing Late-season Influenza Vaccine Responses to Compare the 2023 and 2024 Vaccine Formulations
Influenza A
Primary: Magnitude of Antibody Response After the Late-season 2023 Vaccine — 6; 6; 74; 27 HAI Titer
Phase 1 N=50 Influenza HA Ferritin Vaccine, Alone or in Prime-Boost Regimens With an Influenza DNA Vaccine in Healthy Adults
Influenza
Primary: Number of Subjects Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Each HA-F A/Sing Product Administration — 4; 3; 7; 9 Participants
Phase 2 N=71 A Study to Evaluate the Efficacy, Safety and Immunogenicity of a Vaccine Designed to Protect Against Infection With Shigella Sonnei in Healthy Adults
Dysentery, Bacillary
Primary: Percentage of Subjects With at Least One Episode of Shigellosis According to the Protocol Primary Case Definition — 46.9; 42.9 Percentage of subjects — p=0.4266
Phase 2 N=21 Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir
Hepatitis D
Primary: Number of Participants With Decline of Hepatitis Delta Virus (HDV) RNA Quantitative Measurements of >2 Logs From Baseline at 12 Weeks of Treatment — 1; 1; 1; 0…
Phase 3 N=624 Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers
Dengue · Dengue Hemorrhagic Fever
Primary: Percentage of Participants With Seroprotection or Booster Response After a Booster Injection (Inj.) of Diphtheria, Tetanus, Acellular Pertussis(DTaP)-Inactivated Polio…
Phase 3 N=918 Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers
Meningitis · Meningococcal Meningitis · Meningococcal Infections
Primary: Percentage of Participants With Antibody Titers Greater Than or Equal to (>=) 1:8 Against Meningococcal Serogroups A, C, Y, and W in Toddlers Who Either Were…
Phase 1 N=210 Safety, Immunogenicity, and Protective Efficacy of Two Regimens of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Natural Transmission Season in Healthy African Adults in Mali
Malaria
Primary: Number of Participants With Local and Systemic Adverse Events in Year One — 39; 27; 19; 11 Participants
N/A N=19 Hepatitis A Vaccine Dosing Regimens Among Pediatric Patients on Immunosuppressive Therapy
Autoimmune Rheumatologic Disease
Primary: Hepatitis A Antibodies Titre — 9.4; 9.0; 394.7; 810.6 IU/L
Phase 2 N=21 Ledipasvir/Sofosbuvir for Hepatitis B Virus Infection
Hepatitis B
Primary: Change of Serum Hepatitis B Surface Antigen (HBsAg as Measured in log10 IU/mL) Level as an Indicator of Antiviral Activity of Ledipasvir and/or Sofosbuvir in Subjects…
Phase 2 N=24 Evaluation of Safety, Tolerability, and Antiviral Activity of Chlorcyclizine HCl in Patients With Chronic Hepatitis C
Chronic Hepatitis C
Primary: Change in Serum HCV RNA Viral Titer From Baseline to 28 Days — -0.46; -0.11 log IU/ml